Compile Data Set for Download or QSAR
Report error Found 94 Enz. Inhib. hit(s) with all data for entry = 12059
TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675017(1-(4-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675016(1-(4-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675010(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM674999(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675001(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675000(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM674995(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM674994(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM674996(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675007(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675006(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675009(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675008(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675003(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675005(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675004(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675047(1-(5-(4-amino-7-(piperidin-4- yl)-7H-pyrrolo[2,3-d...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675046(1-(5-(4-amino-7-(pyridin-3-yl)- 7H-pyrrolo[2,3-d]p...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675049(1-(5-(4-amino-1-cyclopropyl- 1H-pyrazolo[3,4-d]pyr...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675043(1-(5-(4-amino-7-(2-hydroxy- 2-methylpropyl)-7H-pyr...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675042(1-(5-(4-amino-7-(2-hydroxy- ethyl)-7H-pyrrolo[2,3-...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675045(1-(5-(4-amino-7-(2-methoxy- ethyl)-7H-pyrrolo[2,3-...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675044(1-(5-(4-amino-7-(3-hydroxy- cyclobutyl)-7H-pyrrolo...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675057(1-(5-(4-amino-7-methyl-7H- pyrrolo[2,3-d]pyrimidin...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675056(1-(5-(4-amino-7-methyl-7H- pyrrolo[2,3-d]pyrimidin...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675051(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675031(1-(4-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675033(1-(4-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675032(1-(4-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675039(1-(7-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675038(1-(7-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675041(1-(5-(4-amino-7-cyclobutyl- 7H-pyrrolo[2,3-d]pyrim...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675040(1-(5-(4-amino-7-isopropyl- 7H-pyrrolo[2,3-d]pyrimi...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675037(1-(7-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675036(1-(7-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675063(1-(5-(4-amino-7-(piperidin-4- yl)-7H-pyrrolo[2,3-d...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675062(1-(5-(4-amino-7-(3-hydroxy- cyclobutyl)-7H-pyrrolo...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675065(1-(5-(4-amino-7-isopropyl- 7H-pyrrolo[2,3-d]pyrimi...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675059(1-(5-(4-amino-7-cyclobutyl- 7H-pyrrolo[2,3-d]pyrim...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675058(1-(5-(4-amino-7-isopropyl- 7H-pyrrolo[2,3-d]pyrimi...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675061(1-(5-(4-amino-7-(2-hydroxy-2- methylpropyl)-7H-pyr...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675060(1-(5-(4-amino-7-(2-hydroxy- ethyl)-7H-pyrrolo[2,3-...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675067(1-(5-(4-amino-7-cyclobutyl- 7H-pyrrolo[2,3-d]pyrim...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM675066(1-(5-(4-amino-7-isopropyl- 7H-pyrrolo[2,3-d]pyrimi...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM674983(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM674982(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM674984(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM674978(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM674981(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM674991(1-(5-(4-amino-7-cyclopropyl- 7H-pyrrolo[2,3-d]pyri...)
Affinity DataIC50: 200nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and κ caseins, obtained from Sigma Aldri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2024
Entry Details
US Patent

Displayed 1 to 50 (of 94 total ) | Next | Last >>
Jump to: